Rigel Pharmaceuticals INC

Rigel Pharmaceuticals announced robust second quarter 2026 financial results, including record net product sales and net income, alongside the strategic in-license of VEPPANU.

Rigel Pharmaceuticals announced a change in its Chief Medical Officer role and a related board resignation, effective July 1, 2026.

Rigel Pharmaceuticals has finalized its exclusive global license agreement for VEPPANU (vepdegestrant) and related products, making an upfront payment of $70.0 million.

Rigel Pharmaceuticals stockholders approved amendments to equity and stock purchase plans, re-elected directors, and ratified auditor selection at the 2026 Annual Meeting.

Rigel Pharmaceuticals has entered into an exclusive worldwide license agreement with Arvinas and Pfizer to commercialize the breast cancer therapy VEPPANU.

Rigel Pharmaceuticals announced first quarter 2026 financial results, reporting $58.8 million in total revenues and $8.7 million in net income, while reaffirming its full-year revenue guidance.

Rigel Pharmaceuticals announced significant revenue growth in the third quarter of 2025, driven by strong product sales across its commercial portfolio, despite the termination of a key CNS development program with Lilly.

Rigel Pharmaceuticals reported a significant turnaround in its second quarter, achieving substantial net income and revenue growth driven by robust product sales and a key collaboration payment.

Rigel Pharmaceuticals achieves profitability in Q1 2025, driven by increased sales of TAVALISSE, REZLIDHIA, and GAVRETO.

Rigel Pharmaceuticals saw a significant increase in revenue during the third quarter of 2024, primarily driven by strong product sales and collaboration revenue.

Rigel Pharmaceuticals' second quarter saw increased product sales offset by higher expenses, while the company advanced its pipeline with new collaborations and a key acquisition.

Rigel Pharmaceuticals' first quarter 2024 results show a revenue increase driven by REZLIDHIA sales, while TAVALISSE sales experienced a slight decrease.

Rigel Pharmaceuticals' 10-K filing reveals a year of increased product sales and strategic pipeline advancements, including the acquisition of GAVRETO and progress in IRAK 1/4 inhibitor development.

Rigel Pharmaceuticals reports a 24% increase in TAVALISSE sales and a significant jump in REZLIDHIA sales, while also acquiring rights to GAVRETO in the US.

Rigel Pharmaceuticals EVP, Chief Medical Officer Alison L. Hannah acquired 24,400 shares of common stock through the vesting of Restricted Stock Units.

Rigel Pharmaceuticals Director Kamil Ali-Jackson sold 2,500 shares of common stock on June 22, 2026, as part of a pre-arranged 10b5-1 trading plan to cover tax withholding obligations.

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, exercised stock options and adjusted common stock holdings, reflecting a recent reverse stock split.

EVP and Chief Commercial Officer David A. Santos disposed of 874 shares of Rigel Pharmaceuticals common stock to cover tax obligations.

Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reported the disposition of 850 shares of common stock.

CEO Raul R. Rodriguez disposed of 2,424 shares of Rigel Pharmaceuticals common stock to satisfy tax withholding obligations.

Rigel Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 14, 2026, to be held virtually.

Rigel Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Rigel Pharmaceuticals is asking stockholders to approve an amendment to its 2018 Equity Incentive Plan to increase the number of shares available for issuance by 700,000.

Rigel Pharmaceuticals has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Rigel Pharmaceuticals is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares, representing 8.95% of Rigel Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

Soleus Capital Master Fund, L.P. and affiliated entities have reported beneficial ownership of 9.9% of Rigel Pharmaceuticals Inc. common stock as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,280,000 shares, representing 6.93% of Rigel Pharmaceuticals, Inc. common stock.

Soleus Capital Master Fund, L.P. and affiliated entities have filed a Schedule 13G reporting a 5.2% beneficial ownership stake in Rigel Pharmaceuticals, Inc.

The Vanguard Group reported a 0% beneficial ownership in Rigel Pharmaceuticals Inc. following an internal corporate realignment.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 3.99% beneficial ownership stake in Rigel Pharmaceuticals, Inc.